Premium
Perampanel in 12 patients with Unverricht‐Lundborg disease
Author(s) -
Crespel Arielle,
Gelisse Philippe,
Tang Ngoc Phuong Loc,
Genton Pierre
Publication year - 2017
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.13662
Subject(s) - myoclonus , perampanel , progressive myoclonus epilepsy , concomitant , medicine , anesthesia , epilepsy , pediatrics , psychology , psychiatry
Summary Objective Perampanel ( PER ) was used in 12 patients with Unverricht‐Lundborg disease ( ULD ) to evaluate its efficacy against myoclonus and seizures. Methods We treated 11 patients with EPM 1 mutations (6 F, 5 M, aged 13–62 years) and a 43‐year‐old man with de novo KCNC 1 mutation. PER was introduced by 2 mg steps at 2–4 week intervals until 6 mg/day, with a possible dose reduction or dose increase. Results Ten patients had a clear clinical response of myoclonus, and five were able to reduce concomitant therapy. Improvement was noted sometimes as soon as with 2 mg/day. Epileptic seizures stopped on PER in the six patients who still had experienced generalized tonic–clonic or myoclonic seizures (100%). Some abatement of efficacy on myoclonus was seen in two patients who still retained some benefit. Weight gain was reported in six patients (50%). Psychological and behavioral side‐effects were observed in six patients (50%) and led to withdrawal of PER in three cases and dose reduction in three, with abatement of the problems. Significance This study provides evidence that for ULD patients, PER may show marked efficacy even in severe cases, particularly against myoclonus, but also against seizures. PER should thus be tried in ULD patients whose seizures are not satisfactorily controlled. Its use is limited because of psychological and behavioral side effects, with higher doses of approximately 6 mg/day or greater likely risk factors.